Dermatology

Plaque Psoriasis

Expert Roundtables Podcast: Biologic Therapy for Plaque Psoriasis in Patients With Cancer

expert perspectives by Tina Bhutani, MD, MAS, FAAD; Adam Friedman, MD, FAAD; Bruce E. Strober, MD, PhD, FAAD

Overview

When a patient with plaque psoriasis has a history of cancer, it creates a challenging scenario in terms of selecting immunomodulatory or immunosuppressive treatments for their psoriasis. In today’s podcast, our featured experts discuss clinical considerations in this population and provide practical insights.

References

Armstrong AW, Blauvelt A, Callis Duffin K, et al. Psoriasis. Nat Rev Dis Primers. 2025;11(1):45. doi:10.1038/s41572-025-00630-5

Lambert JLW, Segaert S, Ghislain PD, et al. Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2). J Eur Acad Dermatol Venereol. 2020;34(9):1914-1923. doi:10.1111/jdv.16683

Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris – part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281-317. doi:10.1111/jdv.16926

Ro C, Ormaza Vera A, Adawi W, Yap A, Enos CW. Assessment of primary malignancy risk after initiation of biologic therapy in patients with psoriasis. JID Innov. 2025;5(6):100397. doi:10.1016/j.xjidi.2025.100397

Profile

Tina Bhutani, MD, MAS, FAAD

CEO, Synergy Dermatology
Associate Clinical Professor
Department of Dermatology
University of California, San Francisco
San Francisco, CA

Profile

Adam Friedman, MD, FAAD

Professor and Chair of Dermatology
Director, Residency, Translational Research, Hidradenitis Suppurativa, and Supportive Oncodermatology Programs
Department of Dermatology
The George Washington University School of Medicine & Health Sciences
Washington, DC